MX2024010584A - Pclx-001 oral en el tratamiento del cancer humano. - Google Patents

Pclx-001 oral en el tratamiento del cancer humano.

Info

Publication number
MX2024010584A
MX2024010584A MX2024010584A MX2024010584A MX2024010584A MX 2024010584 A MX2024010584 A MX 2024010584A MX 2024010584 A MX2024010584 A MX 2024010584A MX 2024010584 A MX2024010584 A MX 2024010584A MX 2024010584 A MX2024010584 A MX 2024010584A
Authority
MX
Mexico
Prior art keywords
pclx
per day
oral
treatment
human cancer
Prior art date
Application number
MX2024010584A
Other languages
English (en)
Spanish (es)
Inventor
John Robert Mackey
Neal Maynard Davies
Original Assignee
Pacylex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacylex Pharmaceuticals Inc filed Critical Pacylex Pharmaceuticals Inc
Publication of MX2024010584A publication Critical patent/MX2024010584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024010584A 2022-03-03 2023-03-03 Pclx-001 oral en el tratamiento del cancer humano. MX2024010584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263316153P 2022-03-03 2022-03-03
PCT/CA2023/050281 WO2023164776A1 (en) 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer

Publications (1)

Publication Number Publication Date
MX2024010584A true MX2024010584A (es) 2024-09-06

Family

ID=87882761

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010584A MX2024010584A (es) 2022-03-03 2023-03-03 Pclx-001 oral en el tratamiento del cancer humano.

Country Status (10)

Country Link
US (1) US20250161299A1 (https=)
EP (1) EP4486344A4 (https=)
JP (1) JP2025507923A (https=)
KR (1) KR20240155234A (https=)
CN (1) CN118829428A (https=)
AU (1) AU2023228703A1 (https=)
CA (1) CA3244234A1 (https=)
IL (1) IL314984A (https=)
MX (1) MX2024010584A (https=)
WO (1) WO2023164776A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025050208A1 (en) * 2023-09-05 2025-03-13 Pacylex Pharmaceuticals Inc. Oral pclx-001 in the treatment of human cancer
CN120361006A (zh) * 2025-05-19 2025-07-25 上海交通大学医学院附属第九人民医院 Nmt1抑制剂及其在制备实体瘤治疗药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
JP7539760B2 (ja) * 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング
GB201820660D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
MX2023004341A (es) * 2020-10-20 2023-05-24 Pacylex Pharmaceuticals Inc Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios.

Also Published As

Publication number Publication date
JP2025507923A (ja) 2025-03-21
CN118829428A (zh) 2024-10-22
WO2023164776A1 (en) 2023-09-07
KR20240155234A (ko) 2024-10-28
AU2023228703A1 (en) 2024-09-12
CA3244234A1 (en) 2023-09-07
EP4486344A4 (en) 2026-03-04
IL314984A (en) 2024-10-01
EP4486344A1 (en) 2025-01-08
US20250161299A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
Nyati et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo
MX2024010584A (es) Pclx-001 oral en el tratamiento del cancer humano.
EA201301270A1 (ru) Способ комбинированного, направленного к egfr лечения рака
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
WO2020030977A3 (en) Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors
CR20200602A (es) Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje
MX2023014131A (es) Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo.
MX2025009943A (es) Derivado de camptotecina, su conjugado, su metodo de preparacion y su uso medico
WO2023046060A8 (zh) 治疗kras突变的癌症患者
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
MX2023009376A (es) Uso de conjugado de anticuerpo-farmaco dirigido a her2 en el tratamiento de cancer de mama especifico.
IL164564A0 (en) Combination therapy for the treatment of cancer
RU2011151854A (ru) Новые терапевтические способы применения инекальцитола
MX2022006877A (es) Uso de un abridor de canal de potasio kv7 para tratar el dolor.
JP2009535298A5 (https=)
US20250205269A1 (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer
WO2016181225A3 (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
WO2000006136A3 (en) Therapeutic combination of polyamine with an anticancer agent
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
EP3127544B1 (en) Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer
RU2639463C1 (ru) Способ лечения острого лучевого эзофагита
MX2024010607A (es) Terapia combinada de un inhibidor de pi3k y un inhibidor de pd-1